口服降糖药转换为胰岛素是否与骨折风险增加相关?
基于意大利伦巴第大区医疗数据库的队列研究,纳入2005至2009年使用口服降糖药的216,624例患者,经倾向评分匹配后分析27,494对胰岛素与口服药转换者。结果显示转换为胰岛素者任何骨折风险增加(HR=1.5),髋部(HR=1.6)和椎体(HR=1.8)骨折风险亦增加,风险差异主要在转换后前2个月显现。
要点
- 口服降糖药转换为胰岛素与任何骨折风险增加相关(HR=1.5,95%CI 1.3-1.6)。
- 髋部骨折HR=1.6(95%CI 1.4-1.8),椎体骨折HR=1.8(95%CI 1.5-2.3)。
- 骨折风险差异主要在转换后前2个月显现,并持续整个随访期但强度减弱。
核心结论
- 口服降糖药转换为胰岛素与骨折风险增加相关,尤其在胰岛素治疗开始后近期。
研究设计与样本
- 基于意大利伦巴第大区医疗利用数据库的观察性队列研究,纳入2005至2009年使用口服降糖药的216,624例患者。
- 136,307例(63%)发生治疗调整,其中28,420例(21%)转换为胰岛素,107,887例(79%)换用其他口服药。
- 采用1:1高维倾向评分匹配,匹配失败926例(3%),最终分析27,494对胰岛素-口服药匹配者,随访至2012年。
主要发现
- 转换为胰岛素者任何骨折风险增加(HR=1.5,95%CI 1.3-1.6,p<0.001)。
- 髋部骨折HR=1.6(95%CI 1.4-1.8,p<0.001),椎体骨折HR=1.8(95%CI 1.5-2.3,p<0.001)。
- 转换后前2个月,胰岛素组每日骨折风险为9例/100,000人日,口服药组为4例/100,000人日,差异持续整个随访期但强度减弱。
临床怎么用
- 处方者和患者应知晓转换为胰岛素后骨折风险增加,尤其在前2个月。
- 应仔细控制胰岛素剂量,并采取措施降低跌倒风险。
局限性
- 观察性设计且缺乏临床数据,无法确定因果关系,需未来研究验证或反驳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies showed that exposure to exogenous insulin increases fracture risk. However, it remains unclear whether the observed association is a function of the severity of underlying type 2 diabetes mellitus, complications, therapies, comorbidities, or all these factors combined. That being so, and because of the relative infrequency of these events, it is important to study this further in a large-database setting. QUESTION/PURPOSES: (1) Is switching from oral antidiabetic agents to insulin associated with an increased fracture risk? (2) How soon after switching does the increased risk appear, and for how long does this increased risk persist? METHODS: Data from healthcare utilization databases of the Italian region of Lombardy were used. These healthcare utilization databases report accurate, complete, and interconnectable information of inpatient and outpatient diagnoses, therapies, and services provided to the almost 10 million residents in the region. The 216,624 patients on treatment with oral antidiabetic therapy from 2005 to 2009 were followed until 2010 to identify those who modified their antidiabetic therapy (step 1 cohort). Among the 63% (136,307 patients) who experienced a therapy modification, 21% (28,420 patients) switched to insulin (active exposure), and the remaining 79% (107,887 patients) changed to another oral medication (referent exposure). A 1:1 high-dimension propensity score matching design was adopted for balancing patients on active and referent exposure. Matching failed for 3% of patients (926 patients), so the cohort of interest was formed by 27,494 insulin-referent couples. The latter were followed until 2012 to identify those who experienced hospital admission for fracture (outcome). A Cox proportional hazard model was fitted to estimate the hazard ratio (HR) for the outcome risk associated with active-exposure (first research question). Between-exposure comparison of daily fracture hazard rates from switching until the 24 successive months was explored through the Kernel-smoothed estimator (second research question). RESULTS: Compared with patients on referent exposure, those who switched to insulin had an increased risk of experiencing any fracture (HR = 1.5 [95% CI 1.3 to 1.6]; p < 0.001). The same risk was observed for hip and vertebral fractures, with HRs of 1.6 (95% CI 1.4 to 1.8; p < 0.001) and 1.8 (95% 1.5 to 2.3; p < 0.001), respectively. Differences in the daily pattern of outcome rates mainly appeared the first 2 months after switching, when the hazard rate of patients on active exposure (9 cases for every 100,000 person-days) was higher than that of patients on referent exposure (4 cases for every 100,000 person-days). These differences persisted during the remaining follow-up, though with reduced intensity. CONCLUSIONS: We found quantitative evidence that switching from oral antidiabetic therapy to insulin is associated with an increased fracture risk, mainly in the period immediately after the start of insulin therapy. The observed association may result from higher hypoglycemia risk among patients on insulin, which leads to a greater number of falls and resulting fractures. However, although our study was based on a large sample size and highly accurate data, its observational design and the lack of clinical data suggest that future research will need to replicate or refute our findings and address the issue of causality, if any. Until then, though, prescribers and patients should be aware of this risk. Careful control of insulin dosage should be maintained and measures taken to reduce fall risk in these patients. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Corrao G, Monzio Compagnoni M, Ronco R, et al. Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? Clin Orthop Relat Res. 2020. PMID: 31842141. doi:10.1097/CORR.0000000000001089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。